AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Scilex Holding (SCLX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.34

-0.01 (-3.08%)

At close: Feb 20, 2025, 3:59 PM

undefined% (undefined)

Bid	0.33
Market Cap	81.51M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.81
PE Ratio (ttm)	-0.41
Forward PE	n/a
Analyst	Buy

Ask	0.34
Volume	741,477
Avg. Volume (20D)	1,446,445
Open	0.35
Previous Close	0.35
Day's Range	0.32 - 0.35
52-Week Range	0.33 - 2.63
Beta	undefined

About SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Mar 5, 2021

Employees 117

Stock Exchange NASDAQ

Ticker Symbol SCLX

Website https://www.scilexholding.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $13.5, which is an increase of 3929.85% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago

-6.39%

Scilex shares are trading lower after the company ... Unlock content with Pro Subscription

2 months ago

-12.75%

Scilex Holding shares are trading lower after the company announced a $17 million registered direct offering.

News

9 months ago · https://www.defenseworld.net

Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison

Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and bluebird bio (NASDAQ:BLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compar...

12 months ago · businesswire.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

1 year ago · pennystocks.com

Penny Stocks To Buy This Week? Analysts Like These 3

Penny stocks are shares of small companies priced under $5 per share. While the potential returns can be alluring, penny stocks carry high risk.

1 year ago · fool.com

Why Shares of Scilex Are Up Monday

Last week, the company said it is hiring a firm to look into manipulation of its stock. The company just got approval in February from the FDA for acute migraine treatment Elyxyb.

1 year ago · benzinga.com

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3 - Sight Sciences (NASDAQ:SGHT), Scilex Holding (NASDAQ:SCLX)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

1 year ago · fool.com

Why Shares of Scilex Are Dropping Monday

Scilex reported positive phase 2 trial data for a lower back pain therapy. The company said it likely saw record revenue in August.

1 year ago · fool.com

Why Shares of Scilex Slumped This Week

While Scilex is not a debtor in Sorrento Therapuetics' bankruptcy proceedings, it is affected by them. Scilex plans to sell $300 million of stock.

1 year ago · investorplace.com

Scilex (SCLX) Stock Fans, Mark Your Calendars for April 17

Scilex (NASDAQ: SCLX ) stock is plunging 15% after the company delayed its 2023 annual meeting from today until April 17. Scilex, which specializes in developing non-opioid pain treatments, indicated ...

2 years ago · seekingalpha.com

A SPAC, Spinoff, And Short Squeeze Walk Into A Bar

Shares of Scilex could trade higher due to hedging pressure from large Sorrento short positions. Scilex's equity offering facilities, mean that the price could fall precipitously at any time via compa...

2 years ago · fool.com

Why Shares of Scilex Soared This Week

Improved revenue estimates and buyout rumors have been driving the stock higher.